EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)Turck, DominiqueCastenmiller, JacquelineDe Henauw, StefaanHirsch-Ernst, Karen IldicoKearney, JohnMaciuk, AlexandreMangelsdorf, IngeMcArdle, Harry JNaska, AndronikiPelaez, CarmenPentieva, KristinaSiani, AlfonsoThies, FrankTsabouri, SophiaVinceti, MarcoCubadda, FrancescoFrenzel, ThomasHeinonen, MarinaMarchelli, RosangelaNeuhäuser-Berthold, MonikaPoulsen, MortenMaradona, Miguel PrietoSchlatter, Josef Rudolfvan Loveren, HenkColombo, PaoloKnutsen, Helle Katrine2021-05-272021-05-272020-11-19EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck, D, Castenmiller, J, De Henauw, S, Hirsch-Ernst, K I, Kearney, J, Maciuk, A, Mangelsdorf, I, McArdle, H J, Naska, A, Pelaez, C, Pentieva, K, Siani, A, Thies, F, Tsabouri, S, Vinceti, M, Cubadda, F, Frenzel, T, Heinonen, M, Marchelli, R, Neuhäuser-Berthold, M, Poulsen, M, Maradona, M P, Schlatter, J R, van Loveren, H, Colombo, P & Knutsen, H K 2020, 'Safety of lacto-N-neotetraose (LNnT) produced by derivative strains of E. coli BL21 as a novel food pursuant to Regulation (EU) 2015/2283', EFSA Journal, vol. 18, no. 11, e06305. https://doi.org/10.2903/j.efsa.2020.63051831-4732PubMedCentral: PMC7676322ORCID: /0000-0002-9275-9713/work/99981887https://hdl.handle.net/2164/16557Requestor: European Commission111285201engSDG 3 - Good Health and Well-beinglacto-N-neotetraoseLNnThuman milk oligosaccharideHiMOnovel foodchange in specificationsfood for specific groupsR MedicineRJournal article10.2903/j.efsa.2020.63051811